Published in PLoS One on February 04, 2016
Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. Int J Oncol (2016) 0.79
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clin Pathol (2016) 0.77
Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomark Res (2016) 0.76
Identification of molecular targets for esophageal carcinoma diagnosis using miRNA-seq and RNA-seq data from The Cancer Genome Atlas: a study of 187 cases. Oncotarget (2017) 0.76
Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol (2016) 0.75
Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. Oncotarget (2016) 0.75
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS One (2016) 0.75
Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Rev Anticancer Ther (2016) 0.75
Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes. Front Oncol (2017) 0.75
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med (2012) 15.43
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 10.17
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol (1994) 4.49
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol (2001) 3.83
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A (2011) 3.38
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul (2006) 3.32
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
HER2 testing in gastric cancer: a practical approach. Mod Pathol (2012) 2.68
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61
Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol (2011) 2.36
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol (1994) 2.20
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol (2014) 2.10
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology (2008) 2.00
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol (2010) 1.83
Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer (2008) 1.78
Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res (2012) 1.74
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer (2007) 1.73
HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res (2010) 1.73
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med (2012) 1.62
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol (2010) 1.54
High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res (2008) 1.38
HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst (2012) 1.37
Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev (2010) 1.34
EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol (2007) 1.28
A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res (2007) 1.28
Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol (2013) 1.28
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer (2013) 1.24
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2013) 1.21
c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology (1994) 1.21
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res (2003) 1.10
Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg (2004) 1.08
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther (2014) 1.05
Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) (2015) 1.05
Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res (2013) 1.03
Regulation of ERBB3/HER3 signaling in cancer. Oncotarget (2014) 1.00
ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis (2009) 0.99
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer (2011) 0.99
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. Int J Cancer (2014) 0.96
High expression of RNA-binding motif protein 3 in esophageal and gastric adenocarcinoma correlates with intestinal metaplasia-associated tumours and independently predicts a reduced risk of recurrence and death. Biomark Res (2014) 0.95
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist (2015) 0.92
Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa. Cancer (2006) 0.92
Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma. J Transl Med (2014) 0.91
Targeted therapy in gastric cancer. APMIS (2015) 0.91
Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opin Investig Drugs (2013) 0.85
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes (2014) 0.85
Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. J Clin Pathol (2015) 0.84
Proficiency testing in immunohistochemistry-experiences from Nordic Immunohistochemical Quality Control (NordiQC). Virchows Arch (2015) 0.83
SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma. Virchows Arch (2014) 0.82
HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer (2013) 0.81
HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver. Acta Oncol (2015) 0.80
HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. Virchows Arch (2015) 0.80
Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology (2015) 0.80
ERBB3 Positively Correlates with Intestinal Stem Cell Markers but Marks a Distinct Non Proliferative Cell Population in Colorectal Cancer. PLoS One (2015) 0.77